Waiv Raises $33M for AI Cancer Diagnostics

Emerging from its former life as a division within AI biotech firm Owkin, Waiv has officially launched as a standalone entity, bolstered by a significant $33 million funding round. This capital infusion is earmarked to propel the development of its advanced AI-driven diagnostic tools, specifically targeting precision oncology. The Paris-based startup is focused on industrializing a new generation of AI-powered tests designed to enhance cancer patient care.

The substantial financing was jointly led by prominent venture capital firms OTB Ventures and Alpha Intelligence Capital (AIC). Further backing came from a consortium of investors including Serena Data Ventures, Karista, and SistaFund. This collective investment underscores strong market confidence in Waiv's mission to revolutionize cancer diagnostics through artificial intelligence.

Waiv's core technology leverages machine learning to analyze complex, multimodal oncology data, with a particular emphasis on digital pathology images. These high-resolution scans offer an unprecedented level of detail regarding a patient's tumor. By applying sophisticated AI models, Waiv's platform can discern subtle biological signatures that are imperceptible to the human eye. This capability is crucial for predicting treatment efficacy, identifying key biomarkers, and refining patient stratification for more personalized therapeutic strategies, a concept the company terms "AI-enabled precision testing."

The company's product suite already includes clinically validated solutions such as RlapsRisk BC, MSIntuit Suite, and BRCAura BC, all focused on breast cancer diagnostics. Additionally, Waiv offers Destra, an adaptable digital pathology platform that seamlessly integrates into existing laboratory and pathologist workflows, allowing for direct access to their diagnostic tests. Revenue generation is primarily based on a per-test model.

Beyond its direct diagnostic offerings, Waiv actively cultivates strategic partnerships within the pharmaceutical sector. These collaborations are vital for discovering novel biomarkers and optimizing patient selection for clinical trials. Notable pharmaceutical allies include Merck & Co., with whom Waiv is working to identify MSI biomarkers in colorectal cancer, and AstraZeneca. This dual focus on clinical diagnostics and pharmaceutical research aligns with a successful strategy seen across the AI in medicine sector.

Leading Waiv is CEO Meriem Sefta, an accomplished executive with a background from institutions like Ecole Polytechnique and MIT, and prior experience at Institut Curie and as Chief Diagnostic Officer at Owkin. Her leadership aims to capitalize on over a decade of dedicated AI research in oncology. Sefta emphasizes that effective precision medicine hinges on accurately guiding patients to their most suitable treatments, highlighting the intricate nature of modern cancer therapy decisions.

The digital pathology market, where Waiv operates, is experiencing rapid expansion, driven by advancements in AI and imaging technology. This sector is becoming increasingly competitive, with players like PathAI, Tempus AI, Foundation Medicine, Caris Life Sciences, and Ibex Medical Analytics vying for market share. Success in this arena is increasingly dependent on the quality of data, the robustness of clinical validation for AI models, and the seamless integration of these tools into established healthcare systems.